Genzyme Sues Endo In Latest Renagel ANDA Suit

Law360, New York (October 6, 2009, 5:32 PM EDT) -- Genzyme Corp. has accused Endo Pharmaceuticals Inc. of infringing a patent for Renagel by seeking regulatory permission to sell a generic version of the kidney disease treatment in the U.S. before the patent expires.

The complaint — filed Thursday in the U.S. District Court for the District of Maryland — cites an Aug. 18 letter the generics maker sent Genzyme informing the company that it had amended it abbreviated new drug application with the U.S. Food and Drug Administration.

The Paragraph IV notice said Endo would...
To view the full article, register now.